Suppr超能文献

发现一种强效且选择性的靶向 NSD2 降解剂,可降低 H3K36me2。

Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.

机构信息

Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.

出版信息

J Am Chem Soc. 2023 Apr 12;145(14):8176-8188. doi: 10.1021/jacs.3c01421. Epub 2023 Mar 28.

Abstract

Nuclear receptor-binding SET domain-containing 2 (NSD2) plays important roles in gene regulation, largely through its ability to dimethylate lysine 36 of histone 3 (H3K36me2). Despite aberrant activity of NSD2 reported in numerous cancers, efforts to selectively inhibit the catalytic activity of this protein with small molecules have been unsuccessful to date. Here, we report the development of UNC8153, a novel NSD2-targeted degrader that potently and selectively reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 through a novel mechanism. Importantly, UNC8153-mediated reduction of H3K36me2 through the degradation of NSD2 results in the downregulation of pathological phenotypes in multiple myeloma cells including mild antiproliferative effects in MM1.S cells containing an activating point mutation and antiadhesive effects in KMS11 cells harboring the t(4;14) translocation that upregulates NSD2 expression.

摘要

核受体结合 SET 域包含蛋白 2(NSD2)在基因调控中发挥重要作用,主要通过其将组蛋白 3(H3)赖氨酸 36 二甲基化的能力(H3K36me2)。尽管在许多癌症中报道了 NSD2 的异常活性,但迄今为止,用小分子选择性抑制该蛋白的催化活性的努力尚未成功。在这里,我们报告了 UNC8153 的开发,这是一种新型的 NSD2 靶向降解剂,能够强烈和选择性地降低 NSD2 蛋白和 H3K36me2 染色质标记的细胞水平。UNC8153 含有一个简单的弹头,通过一种新的机制通过蛋白酶体依赖性降解 NSD2。重要的是,UNC8153 通过降解 NSD2 介导的 H3K36me2 的减少导致多发性骨髓瘤细胞中病理表型的下调,包括含有激活点突变的 MM1.S 细胞中的轻度抗增殖作用和上调 NSD2 表达的 KMS11 细胞中的抗粘附作用。

相似文献

2
Discovery of LLC0424 as a Potent and Selective NSD2 PROTAC Degrader.发现 LLC0424 是一种有效且选择性的 NSD2 PROTAC 降解剂。
J Med Chem. 2024 May 9;67(9):6938-6951. doi: 10.1021/acs.jmedchem.3c01765. Epub 2024 Apr 30.
5
Discovery of NSD2-Degraders from Novel and Selective DEL Hits.新型选择性 DEL 命中物诱导 NSD2 降解剂的发现
Chembiochem. 2023 Dec 14;24(24):e202300515. doi: 10.1002/cbic.202300515. Epub 2023 Oct 24.
10
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).靶向核受体结合 SET 域蛋白 2(NSD2)的药物发现。
J Med Chem. 2023 Aug 24;66(16):10991-11026. doi: 10.1021/acs.jmedchem.3c00948. Epub 2023 Aug 14.

引用本文的文献

4
Covalent Proximity Inducers.共价接近诱导剂
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.
9
Recruitment of FBXO22 for targeted degradation of NSD2.招募 FBXO22 靶向降解 NSD2。
Nat Chem Biol. 2024 Dec;20(12):1597-1607. doi: 10.1038/s41589-024-01660-y. Epub 2024 Jul 4.

本文引用的文献

2
PROTAC targeted protein degraders: the past is prologue.PROTAC 靶向蛋白降解剂:过去是序幕。
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.
4
NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.NSD2 组蛋白 H3K36 二甲基化促进肺腺癌发病机制。
Mol Cell. 2021 Nov 4;81(21):4481-4492.e9. doi: 10.1016/j.molcel.2021.08.034. Epub 2021 Sep 22.
6
Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.发现 NSD2 的 PWWP 结构域的小分子拮抗剂。
J Med Chem. 2021 Feb 11;64(3):1584-1592. doi: 10.1021/acs.jmedchem.0c01768. Epub 2021 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验